The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice
Open accessAbstract
Leukemia immunotherapy frequently does not meet expectation, one of the handicaps being tumor exosome (TEX)‐promoted immunosuppression. We here asked, using the mouse myeloid leukemia WEHI3B and the renal cell carcinoma line RENCA, whether dendritic cell (DC) vaccination suffices to counterregulate TEX‐induced immunosuppression and whether TEX could serve as tumor antigen for DC‐loading. DC‐vaccination significantly prolonged the survival time of WEHI3B‐bearing mice, TEX‐loaded DC (DC‐TEX) being superior to lysate‐loaded DC (DC‐lys), even an excess of TEX not interfering with immune response induction. The superior response to DC‐TEX was accompanied by an increase in WEHI3B‐specific CD4+ T cells, evaluated by trogocytosis and proliferation. Similar findings accounted for DC loaded with RENCA TEX. TEX was efficiently taken‐up by DC and TEX uptake supported CD11c, MHCII and IL12 upregulation in DC. Importantly, TEX was partly recruited into the MHCII‐loading compartment such that “TEX” presentation time and recovery in T cells significantly exceeded that of tumor‐lysate. Thus, TEX did not drive DC into a suppressive phenotype and were a superior antigen due to higher efficacy of TEX‐presentation that is supported by prolonged persistence, preferential processing in the MHCII‐loading compartment and pronounced trogocytosis by T helper cells. TEX is present in tumor patients' sera. TEX, recovered and enriched from patients' sera, might well provide an optimized, individual‐specific antigen source for DC‐loading and vaccination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Christianson, H. C., Svensson, K. J., van Kuppevelt, T. H., Li, J.-P., & Belting, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304266110 · Cited by 903
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869
Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003884 · Cited by 540
Increasing vaccine potency through exosome antigen targeting
Hartman, Z. C., Wei, J., Glass, O. K., Guo, H., Lei, G., Yang, X.-Y., Osada, T., Hobeika, A., Delcayre, A., Le Pecq, J.-B., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.09.133 · Cited by 196
Noerholm, M., Balaj, L., Limperg, T., Salehi, A., Zhu, L. D., Hochberg, F. H., Breakefield, X. O., Carter, B. S., & Skog, J. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-22 · Cited by 190
Cited by
Exosomes: key players in cancer and potential therapeutic strategy
Dai, J., Su, Y., Zhong, S., Cong, L., Liu, B., Yang, J., Tao, Y., He, Z., Chen, C., & Jiang, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00261-0 · Cited by 1,186
Tumor-Derived Exosomes and Their Role in Cancer Progression
(2016) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2015.12.005 · Cited by 755
Dendritic cell subsets in cancer immunity and tumor antigen sensing
Del Prete, A., Salvi, V., Soriani, A., Laffranchi, M., Sozio, F., Bosisio, D., & Sozzani, S. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-00990-6 · Cited by 644
Extracellular vesicles in immunomodulation and tumor progression
Marar, C., Starich, B., & Wirtz, D. (2021) · Nature Immunology · doi:10.1038/s41590-021-00899-0 · Cited by 584
Exosomes and tumor-mediated immune suppression
Whiteside, T. L. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81136 · Cited by 569
Metadata
- Authors
- Gu, X., Erb, U., Büchler, M. W., & Zöller, M.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2014-08-05
- Volume
- 136
- Issue
- 4
- Pages
- E74-84
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2166022006
- Cited by
- 185
- References
- 5
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.